By specifically preventing angiogenesis by VEGFR-2 inhibitors, Figure 1A represents an attractive strategy for the treatment of VEGFR-2-mediated tumor growth, as well as addressing drug resistance [2,3,4]. This evidence concerns the gene KDR and neoplasm.